Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

ss R&D associated with the license discussed below for Clonidine Topical Gel from Arcion Therapeutics (Arcion).

In addition to clinical development activities, BDSI also made an important stride forward in building its pipeline of products for the treatment of pain with the acquisition of patented Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).  BDSI entered into a worldwide licensing agreement with privately held Arcion, where BDSI will develop and commercialize Clonidine Topical Gel. 

The effectiveness of Clonidine Topical Gel was previously assessed in reducing pain in PDN in a double-blind, placebo-controlled, Phase 2 study.  A significant treatment difference was seen in the pain intensity (p=0.01, n=63) in the planned subset analysis of diabetic patients who had documented evidence of functioning pain receptors in the skin of the lower leg.  At a minimum, this supports its effectiveness in diabetic patients with functioning pain receptors in the skin which accounts for approximately one-third to one-half of the nearly 26 million people that according to the American Diabetes Association are suffering from PDN.  BDSI plans to prepare for a confirmatory study in the latter part of 2013 which could lead to data availability by the end of 2014.  The PDN market is highly under-served by existing products, such as the oral medications Lyrica and Cymbalta.  BDSI estimates annual peak sales potential for the product in excess of $300 million in the U.S.

Under terms of the agreement, BDSI made an upfront payment of $2 million to Arcion in the form of unregistered shares of BDSI common stock.  No further milestone payments are due to Arcion until successful completion of the clinical development program and the filing of a New Drug Application (NDA). 

"BDSI continues to make remarkable progress in advancing its pipeline of BEMA products, BUNAVAIL and BEMA Bupren
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Service™
10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... are exposed to sunlight? And how is the skin affected ... subject of research at the University of Gothenburg and Chalmers ... dermatologist conference in Gothenburg. A growing hole in the ... an increase in the number of cases of skin cancer ...
... 12 Beta-Pro LLC, announced today that it ... from pharmaceutical drug discovery and research institutes in ... sciences company now manages extensive laboratory facilities in ... Virginia.   "Beta-Pro has already established ...
... 12 WaferGen Biosystems, Inc. (OTC Bulletin Board: ... analysis systems, today announced that Gary P. Schroth, Ph.D., ... sequencing for gene expression at Illumina, Inc., has joined ... Applications, a new position created to build on the ...
Cached Biology Technology:So that's why we're allergic to sun creams 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 2WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 3WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 4WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 5
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... West Orange, NJ. April 16, 2014. Kessler Foundation ... for $1.8 million from the Department of Defense ... PhD, is principal investigator for the randomized, double-blinded, ... to improve bone and muscle strength after spinal ... Human Performance & Engineering Research at Kessler Foundation. ...
(Date:4/17/2014)... Occurring in about one per eight hundred births, Down ... frequent genetic cause of intellectual disability. It results from ... a third copy of chromosome 21 (1% of the ... his team in the Department of Genetic Medicine and ... Medicine, published in Nature , shed light on ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... Université Laval biologist Connie Lovejoy has discovered new ... findings are reported in the January 12 edition ... discovered a new group of microscopic organisms, which ... extremely small size, measured in millionths of a ...
... to protect against human papillomavirus, has moved from scientific ... to make progress. While HPV vaccine efforts had the ... researchers are developing vaccines for cancers that are not ... system into attacking cancerous cells. Today at the ...
... from West Africa were cracking nuts with stone tools ... The result suggests chimpanzees developed this behaviour on their ... trait inherited from our common ancestor. Julio Mercader, Christophe ... site in Cote d'Ivoire, the only known prehistoric chimpanzee ...
Cached Biology News:Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 2Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 3Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 4Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 5The chimpanzee stone age 2
...
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Liquid. Phycoerythrin conjugate is in PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide....
Biology Products: